GRI Bio presented positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis, IPF. As part of the 2024 ATS International Conference held May 17-22, 2024 in San Diego, CA, Albert Agro, PhD, Chief Medical Officer of GRI Bio presented the poster titled “Altered NKT Cell Populations in the Airways of Patients With IPF,” which presented translational data from IPF patients as well as discussed data demonstrating that in a bleomycin-induced fibrosis model in mice, a selective inhibitor of iNKT cells, GRI-0621, can modulate the fibrotic condition and can reduce the important inflammatory and fibrotic drivers of the disease. Additionally, the design of the Phase 2a study examining the safety, tolerability, and effect on various biomarkers of GRI-0621 was presented.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
- GRI Bio Shares Informational Disclosure Under Regulation FD
- GRI Bio expects cash to fund operations into Q3 of 2024
- GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- GRI Bio files $75M mixed securities shelf